Literature DB >> 1348296

5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

R K Ross1, L Bernstein, R A Lobo, H Shimizu, F Z Stanczyk, M C Pike, B E Henderson.   

Abstract

The incidence of prostate cancer varies widely between countries and ethnic groups. Black-Americans have the highest incidence rates world wide, whereas native Japanese have among the lowest. The reasons for this risk differential are unknown, although we have previously shown that higher circulating testosterone concentrations in young adult black men compared with young adult white men may explain the underlying differences in subsequent prostate cancer incidence between these two populations. We have now compared serum testosterone concentrations in young adult Japanese men with those of young adult whites and blacks, but found no significant differences. However, these white and black men had significantly higher values of 3 alpha, 17 beta androstanediol glucuronide (31% and 25% higher, respectively) and androsterone glucuronide (50% and 41% higher, respectively) than Japanese subjects. These two androgens are indices of 5 alpha-reductase activity. Our results raise the possibility that reduced 5 alpha-reductase activity has a role in producing the low prostate cancer incidence rates among Japanese. This finding may have important implications for prostate cancer prevention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348296     DOI: 10.1016/0140-6736(92)90927-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  79 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 2.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

Review 3.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

4.  A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

Authors:  Ji-An Liang; Li-Min Sun; Ming-Chia Lin; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo; Chia-Hung Kao
Journal:  Oncologist       Date:  2012-06-20

5.  The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.

Authors:  Maarten C Bosland
Journal:  Rev Urol       Date:  2005

6.  Complementary medicine for prostate cancer: effects of soy and fat consumption.

Authors:  M A Moyad; W A Sakr; D Hirano; G J Miller
Journal:  Rev Urol       Date:  2001

7.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

8.  Novel biomarkers for risk of prostate cancer: results from a case-control study.

Authors:  Li Yang; Nilesh W Gaikwad; Jane Meza; Ercole L Cavalieri; Paola Muti; Bruce Trock; Eleanor G Rogan
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

9.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

10.  Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Authors:  Joseph M Unger; Cathee Till; Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; Jason D Wright; William E Barlow; Scott D Ramsey; Lori M Minasian; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2016-08-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.